BidaskClub Lowers Lexicon Pharmaceuticals (LXRX) to Sell

BidaskClub cut shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a hold rating to a sell rating in a research report released on Saturday.

Several other equities analysts also recently weighed in on the company. Zacks Investment Research raised Lexicon Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, March 21st. Needham & Company LLC downgraded Lexicon Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, February 23rd. JPMorgan Chase downgraded Lexicon Pharmaceuticals from a neutral rating to an underweight rating and dropped their price objective for the company from $15.00 to $10.00 in a research note on Wednesday, February 14th. Finally, ValuEngine downgraded Lexicon Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, February 2nd. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $24.50.

NASDAQ LXRX opened at $8.28 on Friday. Lexicon Pharmaceuticals has a 1-year low of $7.80 and a 1-year high of $18.00. The company has a market capitalization of $854.24, a P/E ratio of -6.52 and a beta of 0.40. The company has a quick ratio of 2.58, a current ratio of 2.59 and a debt-to-equity ratio of 4.44.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 143.31% and a negative net margin of 142.86%. The firm had revenue of $33.05 million during the quarter, compared to the consensus estimate of $29.84 million. During the same period last year, the business posted ($0.31) EPS. Lexicon Pharmaceuticals’s quarterly revenue was up 43.7% on a year-over-year basis. equities research analysts expect that Lexicon Pharmaceuticals will post -1.39 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in LXRX. Jump Trading LLC purchased a new position in Lexicon Pharmaceuticals during the fourth quarter worth $104,000. Two Sigma Advisers LP purchased a new position in Lexicon Pharmaceuticals during the fourth quarter worth $104,000. Quantitative Systematic Strategies LLC purchased a new position in Lexicon Pharmaceuticals during the fourth quarter worth $117,000. Aperio Group LLC purchased a new position in Lexicon Pharmaceuticals during the fourth quarter worth $127,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Lexicon Pharmaceuticals during the third quarter worth $149,000.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.